Subacute Combined Degeneration (SCD) of the Spinal Cord

What Is It?

Pathophysiology

1. Methionine synthesis: Cobalamin is a cofactor for methionine synthase, which converts homocysteine to methionine. Methionine is then converted to S-adenosylmethionine (SAM), which is essential for methylation reactions in the nervous system - including myelin maintenance.
2. Methylmalonyl-CoA conversion: Cobalamin is needed to convert methylmalonyl-CoA to succinyl-CoA. When blocked, methylmalonic acid accumulates.

Fig. 1 - Cross-section of spinal cord in SCD (Weigert stain): posterior columns show greater demyelination/axon loss than lateral columns. (Bradley & Daroff, Fig. 85.2)

Causes of B12 Deficiency

• Bradley & Daroff's Neurology, p. 1797; Harrison's 22E, p. 3612

Clinical Presentation

Onset and Pattern

• Onset is insidious and subacute
• Symptoms are typically symmetric and diffuse (not focal)
• The myelopathy is usually ascending

Symptoms (Approximate Order of Appearance)

• Paresthesias (tingling, numbness) in the hands and feet - symmetric, stocking-glove
• Loss of vibration sense and proprioception (posterior column dysfunction)
• Positive Romberg sign
• Lhermitte's sign may be present (electric shock sensation down the spine on neck flexion)

• Progressive leg weakness
• Spastic gait (pyramidal tract involvement - lateral columns)
• Ranging from mild clumsiness to frank spastic paraplegia

• Loss of deep tendon reflexes (due to peripheral neuropathy) combined with upgoing plantars / Babinski sign (due to corticospinal tract involvement) - this combination of areflexia + Babinski is a highly characteristic finding
• Hyperreflexia may also occur when UMN > LMN involvement

• Mental slowing, depression, irritability
• Confusion, delusions, hallucinations ("megaloblastic madness")
• May occasionally be the presenting feature in advanced disease

• Bilateral visual loss, optic atrophy, centrocecal scotomata (optic nerve involvement)
• May precede other neurological symptoms

• Bladder dysfunction (rare)
• Brainstem/cerebellar signs rarely occur
• Harrison's 22E, p. 3612; Bradley & Daroff, p. 1797-1798

Investigations

Haematological

• Macrocytic (megaloblastic) anaemia - macrocytosis, hypersegmented neutrophils
• Important: haematological changes may be absent at the time of neurological presentation - their absence does NOT rule out SCD

Biochemistry

• MMA + homocysteine are especially useful when serum B12 is in the borderline range (200-350 pg/mL)

MRI Spinal Cord (imaging of choice)

• T2-weighted: hyperintense signal in the posterior and lateral columns, typically at cervical/upper thoracic levels
• "Inverted V sign" or "trident sign" on axial T2 - posterior column high signal
• T1-weighted: may show hypointensity in dorsal columns, mild cord enlargement
• Gadolinium enhancement may be present (as in Bradley's Fig. 85.1 case)
• MRI may be normal early in the disease

Fig. 2 - MRI in two cases of SCD: sagittal T2 (A, B) showing posterior column hyperintensity (arrowheads); axial T2 (C, D) showing posterior ± lateral column involvement (arrows). (Bradley & Daroff, eFig. 40.126)

Other Investigations

• Nerve conduction studies: small or absent sural nerve sensory potentials (axonal polyneuropathy in ~50%)
• Somatosensory and visual evoked potentials: may show nonspecific abnormalities
• Diffusion tensor imaging (DTI): more sensitive for white matter changes correlating with cognitive dysfunction

Differential Diagnosis

Management

Treatment Regimen (Parenteral - First-line)

• Days 1-7: 1000 μg intramuscular (IM) cyanocobalamin daily (or hydroxocobalamin)
• Weeks 2-5: 1000 μg IM weekly x 4 weeks
• Maintenance: 1000 μg IM monthly indefinitely (if pernicious anemia or irreversible malabsorption)

• 1000-2000 μg oral cyanocobalamin daily can be used for maintenance (even in pernicious anemia, as ~1-5% passive absorption occurs independently of intrinsic factor)
• Requires close monitoring to confirm adequacy

Monitoring Response to Treatment

• Serum homocysteine and MMA normalize within ~2 weeks of treatment
• Haematological response within weeks
• Neurological improvement is slower - most improvement occurs over the first 6-12 months
• Recovery may be incomplete, especially if diagnosis was delayed
• The key prognostic factor: time between symptom onset and treatment initiation - earlier treatment = better neurological recovery

Prognosis

• Neurological deficits that are present for >3-6 months are less likely to fully recover
• If no improvement occurs at all, consider alternative diagnoses (copper deficiency, HIV myelopathy)
• B12 supplementation does not improve cognitive function in elderly hyperhomocysteinaemic patients without SCD

Management of Underlying Cause

• Harrison's 22E, p. 3612; Bradley & Daroff, pp. 1797-1799; Goldman-Cecil Medicine

Important Clinical Pearls

1. Neurological SCD can precede anaemia - do not dismiss B12 deficiency because the CBC is normal.
2. The combination of absent reflexes + Babinski sign is a classic bedside clue to SCD (peripheral nerve + corticospinal tract involvement simultaneously).
3. Nitrous oxide can precipitate fulminant SCD even after a single dental/surgical anaesthetic in a patient who is already mildly B12 deficient.
4. Serum B12 alone is unreliable - always check MMA and homocysteine if clinical suspicion is high.
5. Copper deficiency myelopathy is the main mimic and must be excluded in cases where B12 is normal (check serum copper, ceruloplasmin; ask about bariatric surgery, zinc supplements).
6. Folate deficiency can produce a similar picture but MMA will be normal (only homocysteine is elevated).

Subacute Combined Degeneration (SCD) of the Spinal Cord

What Is It?

Pathophysiology

1. Methionine synthesis: Cobalamin is a cofactor for methionine synthase (homocysteine → methionine). Methionine → S-adenosylmethionine (SAM), essential for myelin methylation reactions. When SAM fails, myelin maintenance breaks down.
2. Methylmalonyl-CoA conversion: Blocked when cobalamin is absent → methylmalonic acid (MMA) accumulates.

Fig. 1 - SCD cross-section (Weigert stain): posterior columns show greater demyelination/axon loss than lateral columns. (Bradley & Daroff)

Causes of B12 Deficiency

Clinical Presentation

Onset

• Insidious, subacute
• Symptoms are symmetric and diffuse (not focal)

Symptom Sequence

• Paresthesias (tingling, numbness) in hands and feet - symmetric, stocking-glove
• Loss of vibration sense and proprioception (posterior column)
• Positive Romberg sign
• Lhermitte's sign (electric shock down spine on neck flexion) may be present

• Progressive leg weakness, spastic gait (lateral column/corticospinal tract)
• Ranges from mild clumsiness to frank spastic paraplegia

• Absent deep tendon reflexes (peripheral neuropathy) + upgoing plantars/Babinski sign (corticospinal tract) coexisting = hallmark of SCD

• Mental slowing, depression, irritability, confusion
• Delusions, hallucinations ("megaloblastic madness") - may be the presenting feature in advanced cases

• Bilateral visual loss, optic atrophy, centrocecal scotomata (optic nerve involvement)
• May precede other symptoms

• Bladder/autonomic dysfunction
• Brainstem/cerebellar signs
• Reversible coma

Investigations

Haematology

• Macrocytic megaloblastic anaemia, hypersegmented neutrophils
• Important: haematological changes may be absent at neurological presentation - a normal CBC does NOT exclude SCD

Biochemistry

• MMA + homocysteine are critical when serum B12 is borderline (200-350 pg/mL) or when nitrous oxide abuse is suspected (B12 may be normal)

MRI Spine (Imaging of Choice)

• T2-weighted: hyperintense signal in posterior and lateral columns, cervical/upper thoracic levels - "inverted V" or "trident sign" on axial views
• T1-weighted: hypointensity in dorsal columns; may show mild cord swelling
• Gadolinium enhancement may occur
• MRI can be normal early in disease

Fig. 2 - MRI in two SCD cases: sagittal T2 (A, B) showing posterior column hyperintensity (arrowheads); axial T2 (C, D) showing posterior ± lateral column involvement (arrows). (Bradley & Daroff)

Other

• Nerve conduction studies: absent/small sural sensory potentials in ~50% (axonal polyneuropathy)
• Somatosensory/visual evoked potentials: nonspecific abnormalities
• Diffusion tensor imaging: more sensitive for cognitive-correlating white matter changes

Differential Diagnosis

Management

B12 Replacement Regimen

• Week 1: 1000 μg IM cyanocobalamin (or hydroxocobalamin) daily x 5-7 days
• Weeks 2-5: 1000 μg IM weekly x 4 weeks
• Maintenance: 1000 μg IM monthly indefinitely

• 1000-2000 μg oral cyanocobalamin daily - effective even in pernicious anemia due to ~1-5% passive gut absorption (independent of intrinsic factor)
• Requires close monitoring to ensure adequacy

Monitoring Response

• Recovery may be incomplete, especially if diagnosis was delayed
• Key prognostic factor: shorter time from symptom onset to treatment = better neurological recovery

Treat the Underlying Cause

Key Clinical Pearls

1. Neurological SCD can precede anaemia - a normal CBC does not rule out B12 deficiency
2. Absent reflexes + Babinski sign together = classic SCD bedside clue (simultaneous LMN + UMN signs)
3. Nitrous oxide can precipitate fulminant SCD after a single anaesthetic in a mildly deficient patient
4. Serum B12 alone is unreliable - always check MMA and homocysteine if clinical suspicion is high
5. Copper deficiency myelopathy is the principal mimic when B12 is normal
6. Folate deficiency mimics SCD but MMA is normal; homocysteine alone is elevated

Oral vs. IM B12 in SCD - When to Use Which

The Underlying Rationale

• Normal absorption requires intrinsic factor (IF) from gastric parietal cells - this pathway is blocked in pernicious anemia and malabsorption
• But a second, IF-independent passive absorption pathway exists throughout the entire gut, absorbing ~1-5% of any oral dose
• At a dose of 1000-2000 μg orally, that 1-5% = 10-20 μg absorbed - enough to replete stores over time

Decision Framework: IM vs. Oral

Give IM When:

Give Oral (High-Dose) When:

Regimen Summary

What the Evidence Says

• IM ranked highest for raising serum B12 levels (MD +94 pg/mL vs oral), but the difference was not statistically significant
• No significant difference between IM, oral, and sublingual for haemoglobin correction or homocysteine normalisation
• Conclusion: all three routes effectively increase B12 levels; IM is top-ranked but not clinically superior for biochemical endpoints

Bottom Line

The main clinical rule: never gamble on gut absorption when the spinal cord is at stake during the acute/induction phase. Once neurological stability is achieved and stores are replete, a switch to closely monitored high-dose oral therapy is reasonable.

• Sources: Goldman-Cecil Medicine | Bradley & Daroff's Neurology | Symptom to Diagnosis (4th Ed) | Abdelwahab et al. 2024 (PMID 38231320)